Given the synergistic effect of ESR2 in targeted therapy of NSCLC, the present study demonstrated that the combination of the ESR2 inhibitor TPHPP and osimertinib had a greater influence on tumour progression via in vivo and in vitro assays. Here, ESR2 is linked to neoplasm.